Status:
TERMINATED
Secondary Prevention of Atrial Fibrillation (Impact of Renin-Angiotensin-Aldosterone System Inhibition)
Lead Sponsor:
University of Pittsburgh
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
In the present application, we propose to refine and extend current insight into AAF mechanism and therapy by examining the importance of pharmacologic RAAS inhibition, ACE genotype, and their interac...
Eligibility Criteria
Inclusion
- Subjects must be in atrial fibrillation confirmed by 12 lead EKG.
- blood pressure \> 90 mmHg
- Patient without cardiopulmonary symptoms
- 18+ years of age
Exclusion
- Contraindiction to warfarin
- Recent (within 6 months) MI or cardiac revascularization
- Recent (within 6 months) CVA or TIA
- NYHA Class IV CHF
- Active thyroid disease
- Major hepatic dysfunction
- Renal dysfunction (\>2 mg/dL)
- Hyperkalemia (\>4.6 mEq/L)
- Hyponatremia (\<130 mEq/L)
- Currently taking a Vaughn-Williams Type I or III antiarrhythmic drug
- History of ARB intolerance
- Contraindication to ARB therapy
- Pregnancy
- Female of childbearing age
- Age \< 18 years of age
- Inability to give informed consent
- Other medical conditions calling 1 year survival into question
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2007
Estimated Enrollment :
228 Patients enrolled
Trial Details
Trial ID
NCT01233635
Start Date
November 1 2005
End Date
November 1 2007
Last Update
March 23 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UPMC CVI
Pittsburgh, Pennsylvania, United States, 15213